Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2007

Bachmann Hagen S, Otterbach Friedrich, Callies Rainer, Nückel Holger, Bau Maja, Schmid Kurt W, Siffert Winfried, Kimmig Rainer

Abstract excerpt

PURPOSE: Expression of the antiapoptotic and antiproliferative protein Bcl-2 has been repeatedly shown to be associated with better clinical outcome in breast cancer. We recently showed a novel regulatory (-938C>A) single-nucleotide polymorphism (SNP) in the inhibitory P2 BCL2 gene promoter generating significantly different BCL2 promoter activities. EXPERIMENTAL DESIGN: Paraffin-embedded neoplastic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymph Nodes
Share to Lymphatic Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Invasiveness

Share to Polymorphism, Genetic

Share to Proto-Oncogene Proteins c-bcl-2

Share to Time Factors

Share to Treatment Outcome

Source

Identifiers

PMID: 17908970
DOI: 10.1158/1078-0432.CCR-06-2673

Genes

BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.PMID 17908970Read ↗

The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.Semantic proximity Read ↗

Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.Semantic proximity Read ↗

Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.Semantic proximity Read ↗

Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.Semantic proximity Read ↗

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.Semantic proximity Read ↗

Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.Semantic proximity Read ↗

The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.Semantic proximity Read ↗

CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer.Semantic proximity Read ↗

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.Semantic proximity Read ↗

Associations of BCL2 CA-Repeat Polymorphism and Breast Cancer Susceptibility in Isfahan Province of Iran.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.